LuSeed Vascular
Petach Tikva, Israel· Est.
LuSeed Vascular offers a one‑and‑done intrasaccular mesh device to treat all types of brain aneurysms without dual antiplatelet therapy.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
LuSeed Vascular offers a one‑and‑done intrasaccular mesh device to treat all types of brain aneurysms without dual antiplatelet therapy.
NeurovascularCerebrovascular
Technology Platform
Proprietary intrasaccular braided mesh device (LuSeed DOME™) that achieves aneurysm occlusion with minimal parent‑artery protrusion and no need for dual antiplatelet therapy.
Opportunities
Regulatory clearance could open a fast‑growing neurovascular market, especially in centers adopting robotic endovascular platforms and seeking to reduce antiplatelet therapy.
Risk Factors
Dependence on successful regulatory approval, competition from established flow‑diver and coil systems, and the need to demonstrate long‑term safety and efficacy.
Competitive Landscape
Key competitors include Medtronic’s Pipeline, Stryker’s Neuroform, and MicroVention’s LVIS; LuSeed differentiates with a single‑device, antiplatelet‑free solution applicable to both bifurcation and sidewall aneurysms.